Stock Events

Stock Events

Antisense Therapeutics Limited 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 21
€0.07
Nov 20
€0.03
Jul 20
€0.06
Nov 19
€0.03
Jul 19
€0.06
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

2SepExpected
Q4 2025
Next
-0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-8.66MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AWY.MU. It's not an investment recommendation.
Neuren Pharmaceuticals
3
NEU.AU
Alterity Therapeutics
3
ATH.AU
Moleculin Biotech
2
MBRX
Mexedia S.P.A
2
ALMEX.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.19B
Vertex Pharmaceuticals is a key competitor in the cystic fibrosis market, directly competing with Percheron Therapeutics' treatments in this area.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie competes in multiple therapeutic areas including immunology and oncology, overlapping with Percheron's research and drug development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals is involved in biopharmaceuticals targeting genetic disorders, directly competing with Percheron's gene therapy projects.
AMGEN
AMGN
Mkt Cap196.12B
Amgen focuses on human therapeutics in areas like oncology and cardiovascular disease, which are also interest areas for Percheron Therapeutics.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences operates in the field of antiviral drugs, including treatments for HIV, hepatitis B, hepatitis C, and influenza, competing with Percheron's antiviral programs.
Biogen
BIIB
Mkt Cap29.4B
Biogen's focus on neurological diseases and innovative therapies places it in direct competition with Percheron's neurological drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.43B
BioMarin Pharmaceutical targets rare genetic diseases, a field where Percheron is also actively developing treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.89B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing with Percheron's similar efforts in gene silencing technologies.
Novartis
NVS
Mkt Cap293.94B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Percheron Therapeutics is also active, such as cardiovascular, oncology, and neurology.

About

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Show more...
CEO
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBBS
Employees
8
Country
Australia
ISIN
AU000000ANP4
WKN
000A3E1W6

Listings

STU
DE
AWY0.STU
MU
DE
AWY.MU
STU
DE
AWY.STU
MU
DE
AWY0.MU

0 Comments

Share your thoughts

FAQ

What is Antisense Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Antisense Therapeutics Limited stocks are traded under the ticker AWY.MU.
When is the next Antisense Therapeutics Limited earnings date?▼
Antisense Therapeutics Limited is going to release the next earnings report on September 02, 2026.
What were Antisense Therapeutics Limited earnings last quarter?▼
AWY.MU earnings for the last quarter are -0 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Antisense Therapeutics Limited revenue for the last year?▼
Antisense Therapeutics Limited revenue for the last year amounts to 0 EUR.
What is Antisense Therapeutics Limited net income for the last year?▼
AWY.MU net income for the last year is -8.66M EUR.
Does Antisense Therapeutics Limited pay dividends?▼
Yes, AWY.MU dividends are paid annual. The last dividend per share was 0.07 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Antisense Therapeutics Limited have?▼
As of August 14, 2026, the company has 8 employees.
In which sector is Antisense Therapeutics Limited located?▼
Antisense Therapeutics Limited operates in the Other sector.
When did Antisense Therapeutics Limited complete a stock split?▼
The last stock split for Antisense Therapeutics Limited was on December 02, 2016 with a ratio of 6:5.
Where is Antisense Therapeutics Limited headquartered?▼
Antisense Therapeutics Limited is headquartered in Melbourne, Australia.